These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 11422004

  • 1. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes.
    Yeo KR, Yeo WW.
    Br J Clin Pharmacol; 2001 May; 51(5):461-70. PubMed ID: 11422004
    [Abstract] [Full Text] [Related]

  • 2. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
    Prueksaritanont T, Ma B, Tang C, Meng Y, Assang C, Lu P, Reider PJ, Lin JH, Baillie TA.
    Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
    [Abstract] [Full Text] [Related]

  • 3. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A.
    Ma B, Prueksaritanont T, Lin JH.
    Drug Metab Dispos; 2000 Feb; 28(2):125-30. PubMed ID: 10640508
    [Abstract] [Full Text] [Related]

  • 4. Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.
    Wang YH, Jones DR, Hall SD.
    Drug Metab Dispos; 2005 May; 33(5):664-71. PubMed ID: 15689501
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil.
    Renton KW.
    Biochem Pharmacol; 1985 Jul 15; 34(14):2549-53. PubMed ID: 4015695
    [Abstract] [Full Text] [Related]

  • 6. Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites.
    Wang YH, Jones DR, Hall SD.
    Drug Metab Dispos; 2004 Feb 15; 32(2):259-66. PubMed ID: 14744949
    [Abstract] [Full Text] [Related]

  • 7. Effect of benidipine on simvastatin metabolism in human liver microsomes.
    Sugiyama Y, Mimura N, Kuwabara T, Kobayashi H, Ushiki J, Fuse E.
    Drug Metab Pharmacokinet; 2007 Jun 15; 22(3):199-205. PubMed ID: 17603221
    [Abstract] [Full Text] [Related]

  • 8. Role of CYP3A4 in human hepatic diltiazem N-demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites.
    Sutton D, Butler AM, Nadin L, Murray M.
    J Pharmacol Exp Ther; 1997 Jul 15; 282(1):294-300. PubMed ID: 9223567
    [Abstract] [Full Text] [Related]

  • 9. Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.
    Wang JS, Wen X, Backman JT, Taavitsainen P, Neuvonen PJ, Kivistö KT.
    Pharmacol Toxicol; 1999 Oct 15; 85(4):157-61. PubMed ID: 10563513
    [Abstract] [Full Text] [Related]

  • 10. Mechanistic In Vitro Studies Indicate that the Clinical Drug-Drug Interaction between Telithromycin and Simvastatin Acid Is Driven by Time-Dependent Inhibition of CYP3A4 with Minimal Effect on OATP1B1.
    Elsby R, Hare V, Neal H, Outteridge S, Pearson C, Plant K, Gill RU, Butler P, Riley RJ.
    Drug Metab Dispos; 2019 Jan 15; 47(1):1-8. PubMed ID: 30348903
    [Abstract] [Full Text] [Related]

  • 11. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro.
    Polasek TM, Elliot DJ, Lewis BC, Miners JO.
    J Pharmacol Exp Ther; 2004 Dec 15; 311(3):996-1007. PubMed ID: 15304522
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects.
    Yamaori S, Yamazaki H, Iwano S, Kiyotani K, Matsumura K, Honda G, Nakagawa K, Ishizaki T, Kamataki T.
    Drug Metab Pharmacokinet; 2004 Apr 15; 19(2):120-9. PubMed ID: 15499178
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
    Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K.
    Pharm Res; 2006 Mar 15; 23(3):506-12. PubMed ID: 16388406
    [Abstract] [Full Text] [Related]

  • 19. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation.
    Mayhew BS, Jones DR, Hall SD.
    Drug Metab Dispos; 2000 Sep 15; 28(9):1031-7. PubMed ID: 10950845
    [Abstract] [Full Text] [Related]

  • 20. Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
    Choi DH, Choi JS, Li C, Choi JS.
    Pharmacol Rep; 2011 Sep 15; 63(6):1574-82. PubMed ID: 22358108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.